Top-Rated StocksTop-RatedNASDAQ:PGNY Progyny (PGNY) Stock Price, News & Analysis $29.14 +0.54 (+1.89%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$28.77▼$29.2950-Day Range$25.34▼$30.0052-Week Range$23.90▼$44.95Volume611,783 shsAverage Volume911,029 shsMarket Capitalization$2.77 billionP/E Ratio47.77Dividend YieldN/APrice Target$42.40 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Progyny alerts: Email Address Progyny MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.91 Rating ScoreUpside/Downside45.5% Upside$42.40 Price TargetShort InterestBearish9.64% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.53Based on 6 Articles This WeekInsider TradingSelling Shares$456,660 Sold Last QuarterProj. Earnings Growth10.96%From $0.73 to $0.81 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.00 out of 5 starsMedical Sector195th out of 936 stocksMiscellaneous Health & Allied Services, Not Elsewhere Classified Industry1st out of 9 stocks 4.5 Analyst's Opinion Consensus RatingProgyny has received a consensus rating of Moderate Buy. The company's average rating score is 2.91, and is based on 10 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageProgyny has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Progyny's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.64% of the float of Progyny has been sold short.Short Interest Ratio / Days to CoverProgyny has a short interest ratio ("days to cover") of 6.8.Change versus previous monthShort interest in Progyny has recently increased by 3.83%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldProgyny does not currently pay a dividend.Dividend GrowthProgyny does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PGNY. Previous Next 2.0 News and Social Media Coverage News SentimentProgyny has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Progyny this week, compared to 5 articles on an average week.Search InterestOnly 3 people have searched for PGNY on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Progyny to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Progyny insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $456,660.00 in company stock.Percentage Held by Insiders12.30% of the stock of Progyny is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions94.93% of the stock of Progyny is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Progyny's insider trading history. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Progyny are expected to grow by 10.96% in the coming year, from $0.73 to $0.81 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Progyny is 47.77, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 143.05.Price to Earnings Ratio vs. SectorThe P/E ratio of Progyny is 47.77, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 156.27.Price to Earnings Growth RatioProgyny has a PEG Ratio of 1.81. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioProgyny has a P/B Ratio of 5.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Progyny's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just released the details on what he’s calling Elon’s Project X-9840. Click here to see the details because there’s not much time to prepare. About Progyny Stock (NASDAQ:PGNY)Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides assistance service programs where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.Read More PGNY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PGNY Stock News HeadlinesJuly 20, 2024 | insidertrades.comMichael E. Sturmer Sells 9,030 Shares of Progyny, Inc. (NASDAQ:PGNY) StockJuly 3, 2024 | insidertrades.comProgyny, Inc. (NASDAQ:PGNY) Director Cheryl Scott Sells 1,462 SharesJuly 27, 2024 | Weiss Ratings (Ad)Nvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.July 24 at 12:32 PM | finance.yahoo.comThe Broken Brown Egg and Progyny Announce the 2024 Awareness, Hope, and Activism Grant™ to Support BIPOC Individuals and Couples in Family BuildingJuly 23, 2024 | globenewswire.comProgyny, Inc. Announces Details for Its Second Quarter 2024 Results ReportJuly 20, 2024 | americanbankingnews.comProgyny, Inc. Expected to Earn FY2025 Earnings of $0.86 Per Share (NASDAQ:PGNY)July 12, 2024 | seekingalpha.comProgyny: Recent Stock Decline Provides Buying OpportunityJuly 12, 2024 | globenewswire.comAssisted Reproductive Technology Market Report 2024-2033: Vitrolife Leads the Competition with 9.8% Share, Followed by Ferring, and ProgynyJuly 27, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.June 26, 2024 | globenewswire.comProgyny, Inc. to Host 2024 Inaugural Investor DayJune 24, 2024 | globenewswire.comProgyny, Inc. Announces Enhanced Global Services with Acquisition of AprylJune 11, 2024 | prnewswire.comFertility Pioneer and Kindbody Founder Gina Bartasi Returns as CEO to Lead Company's Next Phase of GrowthJune 10, 2024 | seekingalpha.comProgyny: At This Price, Secular Tailwinds Are Too Compelling To IgnoreJune 4, 2024 | globenewswire.comProgyny, Inc. to Present at Jefferies Global Healthcare ConferenceJune 3, 2024 | seekingalpha.comProgyny: No Change To Long-Term OutlookMay 22, 2024 | msn.comProgyny’s board approves another $100 million stock buybackMay 22, 2024 | globenewswire.comProgyny, Inc. Announces Additional Share Repurchase ProgramMay 14, 2024 | globenewswire.comProgyny, Inc. to Present at BofA Securities 2024 Healthcare Conference and Leerink Partners Healthcare Crossroads Conference 2024See More Headlines Receive PGNY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Progyny and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Confirmed)8/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Miscellaneous health & allied services, not elsewhere classified Sub-IndustryN/A Current SymbolNASDAQ:PGNY CUSIPN/A CIK1551306 Webwww.progyny.com Phone212-888-3124FaxN/AEmployees563Year Founded2008Price Target and Rating Average Stock Price Target$42.40 High Stock Price Target$57.00 Low Stock Price Target$30.00 Potential Upside/Downside+45.5%Consensus RatingModerate Buy Rating Score (0-4)2.91 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)$0.61 Trailing P/E Ratio47.77 Forward P/E Ratio39.92 P/E Growth1.81Net Income$62.04 million Net Margins5.53% Pretax Margin6.94% Return on Equity11.61% Return on Assets8.28% Debt Debt-to-Equity RatioN/A Current Ratio3.31 Quick Ratio3.31 Sales & Book Value Annual Sales$1.09 billion Price / Sales2.55 Cash Flow$0.70 per share Price / Cash Flow41.69 Book Value$5.77 per share Price / Book5.05Miscellaneous Outstanding Shares95,220,000Free Float83,509,000Market Cap$2.77 billion OptionableOptionable Beta1.46 Social Links These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. David J. Schlanger (Age 65)Executive Chairman Comp: $513.57kMr. Peter Anevski (Age 57)CEO & Director Comp: $1.09MMr. Michael Sturmer (Age 47)President Comp: $836.49kMr. Mark S. Livingston (Age 58)Chief Financial Officer Comp: $749.56kMs. Allison Swartz (Age 34)Executive VP, General Counsel & Secretary Comp: $546.22kMr. Steven LeistChief Technology OfficerMr. James HartVice President of Investor RelationsMs. Risa FisherChief Marketing OfficerMs. Cassandra PrattChief Human Resources OfficerMs. Julie StadlbauerChief Business Development OfficerMore ExecutivesKey CompetitorsTivity HealthNASDAQ:TVTYSotera HealthNASDAQ:SHCagilon healthNYSE:AGLAmerican Renal AssociatesNYSE:ARAViemed HealthcareNASDAQ:VMDView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 22,012 shares on 7/26/2024Ownership: 0.794%State of Michigan Retirement SystemSold 500 shares on 7/26/2024Ownership: 0.021%RiverPark Advisors LLCBought 474 shares on 7/26/2024Ownership: 0.006%Baillie Gifford & Co.Sold 239,110 shares on 7/25/2024Ownership: 0.915%Louisiana State Employees Retirement SystemSold 600 shares on 7/24/2024Ownership: 0.025%View All Insider TransactionsView All Institutional Transactions PGNY Stock Analysis - Frequently Asked Questions How have PGNY shares performed this year? Progyny's stock was trading at $37.18 at the beginning of the year. Since then, PGNY shares have decreased by 21.6% and is now trading at $29.14. View the best growth stocks for 2024 here. How were Progyny's earnings last quarter? Progyny, Inc. (NASDAQ:PGNY) posted its earnings results on Thursday, May, 9th. The company reported $0.17 earnings per share for the quarter, topping the consensus estimate of $0.14 by $0.03. The firm's quarterly revenue was up 7.6% compared to the same quarter last year. What is David Schlanger's approval rating as Progyny's CEO? 25 employees have rated Progyny Chief Executive Officer David Schlanger on Glassdoor.com. David Schlanger has an approval rating of 89% among the company's employees. When did Progyny IPO? Progyny (PGNY) raised $150 million in an IPO on Friday, October 25th 2019. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Citigroup, Piper Jaffray, SVB Leerink and TPG Capital were co-managers. Who are Progyny's major shareholders? Progyny's top institutional investors include Baillie Gifford & Co. (0.91%), Bank of New York Mellon Corp (0.79%), Carnegie Investment Counsel (0.21%) and Retirement Systems of Alabama (0.11%). Insiders that own company stock include Tpg Gp A, Llc, Michael E Sturmer, Norman Payson, Peter Anevski, David J Schlanger, Mark S Livingston, Cheryl Scott, Kevin K Gordon and Jennifer Bealer. View institutional ownership trends. How do I buy shares of Progyny? Shares of PGNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Progyny own? Based on aggregate information from My MarketBeat watchlists, some other companies that Progyny investors own include NVIDIA (NVDA), Alibaba Group (BABA), Salesforce (CRM), Marvell Technology (MRVL), Alteryx (AYX), Micron Technology (MU) and AbbVie (ABBV). This page (NASDAQ:PGNY) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored4 Steps to Survive the Coming Market CrashCracks threaten us with a widespread collapse unlike anything we've seen in our lifetime. During this prese...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Progyny, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Progyny With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
